Novacyt (LON:NCYT) Issues Earnings Results

Novacyt (LON:NCYT) released its earnings results on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative return on equity of 96.44% and a negative net margin of 103.08%.

Novacyt Stock Down 0.5%

Shares of Novacyt stock traded down GBX 0.21 on Friday, reaching GBX 39.79. The company’s stock had a trading volume of 121,532 shares, compared to its average volume of 174,250. Novacyt has a 52 week low of GBX 26.60 and a 52 week high of GBX 86. The firm’s fifty day simple moving average is GBX 41.85 and its two-hundred day simple moving average is GBX 39.18. The company has a quick ratio of 4.46, a current ratio of 4.74 and a debt-to-equity ratio of 44.74. The company has a market capitalization of £28.85 million, a price-to-earnings ratio of -1.24 and a beta of 1.11.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.